Lenalidomid Stada Nordic

Lenalidomide, the active ingredient in Lenalidomid Stada Nordic, is an immunomodulatory agent presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomid Stada Nordic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical and commercial use with reliable logistics and documentation support.

Lenalidomide is used in hematologic malignancies where it modulates immune response and inhibits tumor growth.

- Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic remission in eligible adults. - Mantle cell lymphoma: enhances response when combined with rituximab in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count leading to infection risk. - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach often occurring after dosing. - Diarrhea: loose stools that may require hydration. - Rash: mild skin eruptions or itching. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil levels requiring medical intervention. - Secondary primary malignancies: emergence of new cancers during therapy. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: irregular heart rhythms observed in rare cases.

When prescribing lenalidomide, clinicians should observe several safety measures to minimize risks. - Pregnancy: contraindicated (Category X); ensure effective contraception for both patient and male partners. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Renal impairment: evaluate kidney function and adjust dose if necessary. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Lenalidomide interacts with several agents; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure and toxicity. - Live vaccines: risk of uncontrolled infection due to immunosuppression. - Thalidomide or pomalidomide: additive teratogenic and hematologic toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): monitor coagulation parameters for bleeding risk. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide effectiveness. - NSAIDs: increase risk of renal dysfunction and gastrointestinal bleeding. - Immunosuppressants (e.g., cyclosporine): may enhance immunomodulatory effects.